The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? [Globe and Mail, The (Toronto, Canada)]
MoonLake Immunotherapeutics (MLTX) had its "buy" rating reaffirmed by BTIG Research. They now have a $30.00 price target on the stock.
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting [Yahoo! Finance]
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
MoonLake Immunotherapeutics (MLTX) was upgraded by Wolfe Research from "underperform" to "outperform". They now have a $24.00 price target on the stock.